VC  Vatera Healthcare Partners

http://www.vaterahealthcare.com/





     Office Locations:

499 Park Avenue, 23rd Floor
New York, NY 10022
Phone: 212-590-2950
Fax: 212-590-2951

 

Stages:

  • Early


 

Industries:

  • Life Sciences & Healthcare

  •  

    Description:

    Founded in 2007, Vatera Healthcare Partners is a venture capital firm focused on investing in biopharmaceutical firms and products, with the goal identifying and developing best-in-class therapies to treat unmet medical needs and improve patients' lives. Vatera aims to build companies by leveraging the team's collective experience and expertise in the pharmaceutical industry and strong network of relationships within industry and academia.



    Investment Firm Key

       VC = Venture Capital
       PE = Private Equity
       A = Angel
       I = Incubator
       MB = Merchant Bank
       VD = Venture Debt
       FI = Family Investment Office
       FOF = Fund of Funds
       ED = Economic Development Office   
       TT = Technology Transfer Office
       CVC = Corporate Venture Capital
       SEC = Secondary Purchaser
       HF = Hedge Fund/Mutual Fund
       
       
       
    COMPANY STAGEREVENUE
    Venture Capital
    Seed Stage
    (includes "pre-seed," or
    concept stage)
    No Revenue
    Early StageMinimal
    Revenue
    Growth Stage
    (also called Mid-stage)
    $2M-$7M
    Expansion Stage
    (also called Late-stage)
    $7M and greater
    Private Equity
    Lower Middle Market$10M-$249M
    Middle Market$250M-$499M
    Upper Middle Market$500M-$1B
    Large Cap>$1B
       
       
     

    Investment Team:


    Name   Title
    Get the complete investment team + individual email addresses for investment team partners. Get personal images, LinkedIn links, investment specialties, office locations and more with a National Database subscription or New York Database subscription.
    Anna Lee Kim General Counsel
    Christopher William Burden COO
    Kevin Thomas Ferro CEO
    Michael Jaharis Founder
    Sundar Kodiyalam Managing Director

     

    Recent Funding Events (trailing 12 months):


      Date


      Name


      State


      Amount


      Stage


      11/14/2017


      ImmusanT


      MA


      $40,000,000


      Series C


     

    Portfolio companies include:

     

    Recent News: